Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 13/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3792783 | 1.00 | KIF11 (0.50) | KIF11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL27148055 | 1.00 | KIF11 (0.50) | KIF11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL28482917 | 1.00 | KIF11 (0.50) | KIF11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL18670133 | 1.00 | KIF11 (0.50) | KIF11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2634426 | 1.00 | KIF11 (0.50) | KIF11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL28487494 | 1.00 | KIF11 (0.50) | KIF11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL15144366 | 1.00 | KIF11 (0.50) | KIF11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3087541 | 0.98 | KIF11 (0.52) | KIF11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL329636 | 0.93 | ALDH1A1 (0.55) | KIF11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL23405872 | 0.90 | KIF11 (0.50) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111793106-A | Polypeptide helix conformation stabilizing method | 安徽大学 | 2020-10-20 | — | — | CN | claimed |
| EP-4736881-A2 | CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY | Ascendis Pharma Growth Disorders A/S (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-4275677-B1 | DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2026-04-29 | — | — | EP | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | ASCENDIS PHARMA A/S (DK) | 2026-04-07 | — | — | US | disclosed |
| EP-4710947-A2 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | Ascendis Pharma Growth Disorders A/S (DK) | 2026-03-18 | — | — | EP | disclosed |
| EP-3400065-B1 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2025-12-17 | — | — | EP | disclosed |
| US-12453778-B2 | Incremental dose finding in controlled-release PTH compounds | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2025-10-28 | — | — | US | disclosed |
| US-20250302924-A1 | Controlled-Release PTH Compound | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2025-10-02 | — | — | US | disclosed |
| US-20250268988-A1 | PTH Prodrugs | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2025-08-28 | — | — | US | disclosed |
| EP-0742790-A4 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS INC (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0804456-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5681941-A | GENETIC ENGINEERING; CROSSLINKING OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1997-10-28 | — | — | US | disclosed |
| US-5578718-A | Thiol-derivatized nucleosides | ISIS PHARMACEUTICALS, INC. (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0742790-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0716604-A1 | THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1996-06-19 | — | — | EP | disclosed |
| WO-1996011205-A9 | PEPTIDE NUCLEIC ACID CONJUGATES | — | 1996-05-30 | — | — | WO | disclosed |
| WO-1996011205-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-18 | — | — | WO | disclosed |
| WO-1995021184-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995006474-A1 | THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268988-A1 | PTH Prodrugs | PTH1R, PTMS, PHPT1 | KIF11 4271/4885HDAC3 1712/4885HDAC4 1201/4885 |
| US-20250302924-A1 | Controlled-Release PTH Compound | PTH1R, CALCA, CALCB | KIF11 1861/4885HDAC3 2117/4885HDAC4 1108/4885 |
| US-12453778-B2 | Incremental dose finding in controlled-release PTH compounds | PTH1R, CALCA, CALCB | KIF11 2832/4885HDAC3 2349/4885HDAC4 1441/4885 |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | CD44, H1-0, MMP1 | KIF11 2789/4885HDAC3 100/4885HDAC4 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.